Clinical trials: Asthma, Allergic
Allergy, Asthma
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
Immunotherapy may help reduce symptoms of allergy and asthma. Problems concerning compliance and adverse events with subcutaneous allergen immunotherapy have generated interest in delivering immunotherapy sublingually (under the…
- Trial name
- SCSS (NCT00434421)
- Testing
- Glycerinated German cockroach allergenic extract
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced…
- Trial name
- NCT02478398
- Testing
- Short ragweed pollen allergen extract, Self-injectable epinephrine, Albuterol/Salbutamol
- Volunteers
- 1,025 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma, Perennial Allergic Rhinitis
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.
- Trial name
- NCT01221285
- Testing
- German cockroach (Blattella germanica) allergenic extract
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Asthma
Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety…
- Trial name
- NCT01405963
- Testing
- Tezepelumab
- Where
- 5 sites in Canada
- Volunteers
- 31 people
- Sponsor
- Amgen
Asthma
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with…
- Trial name
- NCT00454051
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Allergic Asthma
Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
Efficacy/ safety for the combination of anti-IgE (Omalizumab) and specific immunotherapy (Depigoid) in patients with not adequately controlled seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT00396409
- Testing
- Depigoid, Omalizumab
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Allergic Asthma
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
A single center pilot study to determine the protective effects of RhuMAB-E25 on airway physiology and biology in allergic asthmatics that undergo bronchoprovocation with methacholine.
- Trial name
- NCT00829179
- Testing
- RhuMab-E25
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Asthma
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments - omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in inner-city children and adolescents with…
- Trial name
- PROSE (NCT01430403)
- Testing
- Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS)
- Where
- 8 sites in United States
- Volunteers
- 478 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma
This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.
- Trial name
- NCT04987944
- Testing
- Zavegepant
- Where
- 10 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Pfizer
Asthma Atopic
Identification of Allergic Asthmatics Reactive to Felis Catus (Cat Hair) Allergen Inhalation
This study is designed to identify Felis Catus, or cat hair, sensitive asthmatics who demonstrate a late phase asthmatic response after cat hair inhalation.
- Trial name
- NCT03780387
- Testing
- Felis Catus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Asthma
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
- Trial name
- NCT03100825
- Testing
- QVM149
- Where
- 25 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis